[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352816-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352816-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multi-omics-reveals-key-molecular-and-cellular-features-of-advanced-small-cell-lung-cancers-associated-with-distinct-therapeutic-opportunities","Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities","","Small cell lung cancer (SCLC) is highly aggressive and commonly diagnosed at an advanced stage, limiting access to tumor tissue and slowing large-scale multi-omics research. Using methylation profiling of 82 fresh EBUS-TBNA aspirates, with subsets analyzed by whole-genome sequencing, RNA-seq, and blood cfDNA sequencing, the study delineates four molecular subgroups. These groups correlate with survival differences and distinct intrinsic and extrinsic tumor features, including immune-enriched states and potential therapy-linked targets.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multi-omics-reveals-key-molecular-and-cellular-features-of-advanced-small-cell-lung-cancers-associated-with-distinct-therapeutic-opportunities/352816/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multi-omics-reveals-key-molecular-and-cellular-features-of-advanced-small-cell-lung-cancers-associated-with-distinct-therapeutic-opportunities/352816.png","ImageObject",300,407,{"name":42,"@type":43},"Fahsai","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are large omics studies difficult in small cell lung cancer (SCLC)?","Question",{"text":63,"@type":64},"SCLC is often diagnosed at an advanced stage, making surgery unfeasible, and tumor tissue availability is limited. Rapid clinical decline also hinders feasibility of large omics efforts.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What multi-omics approaches were used in this study?",{"text":68,"@type":64},"Methylation profiling was performed on 82 fresh EBUS-TBNA aspirates using EPIC arrays, with subsets undergoing whole-genome sequencing, RNA-seq, and blood cfDNA sequencing.",{"name":70,"@type":61,"acceptedAnswer":71},"How many molecular subgroups were identified and what did they relate to?",{"text":72,"@type":64},"Four methylation-defined subgroups were identified, each associated with distinct survival and tumor features. The groups differed in immune enrichment and expression of transcription factors and potential therapeutic targets.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352816,1790395525,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Nones et al. Genome Medicine (2026) 18:47 [https://doi.org/10.1186/s13073-026-01624-y](https://doi.org/10.1186/s13073-026-01624-y)  \nGenome Medicine  \nRESEARCH Open Access  \nMulti-omics reveals key molecular and cellular  features of advanced small cell lung  \ncancers associated with distinct therapeutic opportunities  \nKatia Nones1,2*†, Vanessa Lakis1,2†, Andrew J. Dalley3, Kimberley Ryan4,5, Haarika Chittoory3, Kaltin Ferguson3,  \nKate Fitzgerald3, Felicity Newell2, LambrosT. Koufariotis2, Farzad Bashirzadeh4, Jung Hwa Son4, Mahendra Singh6, Lakshmy Nandakumar6, David Fairbairn6, Margaret Cummings3,6, Daniel Steinfort7,8, Jemma J. Christie7,8,  \nMatthew Gibney7, Jonathan P. Williamson9, Andrew Pattison10, Louise McIntosh10, Carl Pahoff11, Phan Tien Nguyen 12, Jelena Solujic12, Michael Brown 12, Scott Twaddell13, David Arnold13, Christopher Grainge13, Shailendra Gune14, Oliver Holmes2, Conrad Leonard2, Scott Wood2, John V. Pearson2, Sunil R. Lakhani3,6, Peter T. Simpson3,15†,  \nNicola Waddell2,15† and David Fielding1,3,4†  \nAbstract  \nBackground Small cell lung cancer (SCLC) is an aggressive disease that is often diagnosed at an advanced stage when surgery is no longer feasible. The lack of tumor tissue and rapid clinical decline of patients have hindered the feasibility of large omics studies. However, with advances in omics technologies recent studies have started to unravel the molecular heterogeneity of SCLCs.  \nMethods Here, 82 fresh EBUS-TBNA aspirates underwent methylation profiling (EPIC arrays), with subsets of  \nthose subjected to whole-genome sequencing (n = 76), RNA-seq (n = 48) and blood cfDNA sequencing (n = 69) to characterize the molecular features of SCLCs.  \nResults Methylation profiling revealed four sub-groups associated with distinct survival and extrinsic/intrinsic tumor features. Groups 1 and 2 presented increased expression of ASCL1 . Group 1 tumors had a greater proportion of  \nCD8 + T cells (immune enriched-NE) and patients with better survival. Group 2 (SCLC-A) harbored the largest number of cases, and high expression of SLFN11 and DLL3, as potential therapeutic options. Group 3 tumors presented increased expression and hypomethylation of NEUROD1 (SCLC-N), with a greater proportion offibroblasts. Group 4 tumors expressed POU2F3 and/or YAP1, had increased expression of non-neuroendocrine genes (non-NE) and had the  \n†Katia Nones, Vanessa Lakis, Peter T. Simpson, Nicola Waddell and David Fielding contributed equally to this work.  \n*Correspondence: Katia Nones[k.nones@uq.edu.au](k.nones@uq.edu.au)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nNones et al. Genome Medicine (2026) 18:47 Page 2 of 17  \nworst survival. TACSTD2 expression was higher in Group 4, suggesting a potential therapeutic option for this group. SEZ6, another potential therapeutic o","cbCaibQ9BKlQJ9SA","https://ap.wps.com/l/cbCaibQ9BKlQJ9SA","pdf",5259669,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords","[{\"question\":\"Why are large omics studies difficult in small cell lung cancer (SCLC)?\",\"answer\":\"SCLC is often diagnosed at an advanced stage, making surgery unfeasible, and tumor tissue availability is limited. Rapid clinical decline also hinders feasibility of large omics efforts.\"},{\"question\":\"What multi-omics approaches were used in this study?\",\"answer\":\"Methylation profiling was performed on 82 fresh EBUS-TBNA aspirates using EPIC arrays, with subsets undergoing whole-genome sequencing, RNA-seq, and blood cfDNA sequencing.\"},{\"question\":\"How many molecular subgroups were identified and what did they relate to?\",\"answer\":\"Four methylation-defined subgroups were identified, each associated with distinct survival and tumor features. The groups differed in immune enrichment and expression of transcription factors and potential therapeutic targets.\"}]","Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities | PDF",1790101520,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/098fc08553be175dd66fbf92e0a25a5d.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b15f7fbd2b2be8beeccccc33e6329389.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b30b1bd6ea53adcc9f598fe622d6c1c.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a11688781c48ff27cac2442f3237d402.webp",980,1306]